Marcello Arca

List of Publications by Year in Descending Order

170 papers	6,212 citations	42 h-index	72 g-index
186 ext. papers	7,405 ext. citations	6.1 avg, IF	5.4 L-index

#	Paper	IF	Citations
170	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.. *Lancet, The*, **2022**,	40	4
169	New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia. *Heart Failure Clinics*, **2022**, 18, 177-188	3.3	4
168	Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations.. *Journal of the American Heart Association*, **2022**, e023668	6	2
167	Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. *Journal of Cardiovascular Medicine*, **2021**, 22, 151-161	1.9	26
166	Refinement of pathogenicity classification of variants associated with familial hypercholesterolemia: Implications for clinical diagnosis. *Journal of Clinical Lipidology*, **2021**,	4.9	2
165	Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study. *Journal of Internal Medicine*, **2021**, 290, 116-128	10.8	11
164	Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol in clinical practice: ANMCO position paper. *Journal of Cardiovascular Medicine*, **2021**, 22, 609-617	1.9	2
163	Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events. *Journal of the American Heart Association*, **2021**, 10, e018932	6	7
162	Elevated Serum Concentrations of Remnant Cholesterol Associate with Increased Carotid Intima-Media Thickness in Children and Adolescents. *Journal of Pediatrics*, **2021**, 232, 133-139.e1	3.6	0
161	Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	6
160	High TG to HDL ratio plays a significant role on atherosclerosis extension in prediabetes and newly diagnosed type 2 diabetes subjects. *Diabetes/Metabolism Research and Reviews*, **2021**, 37, e3367	7.5	13
159	CT texture-based radiomics analysis of carotid arteries identifies vulnerable patients: a preliminary outcome study. *Neuroradiology*, **2021**, 63, 1043-1052	3.2	2
158	Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy. *Journal of Clinical Lipidology*, **2021**, 15, 68-78	4.9	24
157	Is it Time for Single-Pill Combinations in Dyslipidemia?. *American Journal of Cardiovascular Drugs*, **2021**, 1	4	2
156	Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe Methodology and rationale for the multinational observational SANTORINI study. *Atherosclerosis Plus*, **2021**, 43, 24-30		2
155	Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile. *Atherosclerosis Plus*, **2021**, 43, 7-9		1
154	Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. *Orphanet Journal of Rare Diseases*, **2021**, 16, 381	4.2	1

153	Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS). *Current Atherosclerosis Reports*, **2021**, 23, 65	6	3
152	The Interplay between Angiopoietin-Like Proteins and Adipose Tissue: Another Piece of the Relationship between Adiposopathy and Cardiometabolic Diseases?. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	9
151	The role of lipid metabolism in shaping the expansion and the function of regulatory T cells.. *Clinical and Experimental Immunology*, **2021**,	6.2	1
150	Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry. *International Journal of Cardiology*, **2020**, 316, 229-235	3.2	7
149	Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. *Current Atherosclerosis Reports*, **2020**, 22, 18	6	14
148	ANGPTL3 deficiency alters the lipid profile and metabolism of cultured hepatocytes and human lipoproteins. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2020**, 1865, 158679	5	4
147	Autosomal recessive hypercholesterolemia: update for 2020. *Current Opinion in Lipidology*, **2020**, 31, 56-61	4.4	9
146	Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review. *Advances in Therapy*, **2020**, 37, 1724-1736	4.1	15
145	Familial combined hypolipidemia: angiopoietin-like protein-3 deficiency. *Current Opinion in Lipidology*, **2020**, 31, 41-48	4.4	16
144	Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries. *Cardiovascular Therapeutics*, **2020**, 2020, 3856242	3.3	5
143	Progression of chronic kidney disease in familial LCAT deficiency: a follow-up of the Italian cohort. *Journal of Lipid Research*, **2020**, 61, 1784-1788	6.3	10
142	How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia. *Atherosclerosis Supplements*, **2020**, 42, e35-e40	1.7	1
141	Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study. *Nutrition, Metabolism and Cardiovascular Diseases*, **2020**, 30, 2027-2035	4.5	4
140	Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia. *Expert Opinion on Pharmacotherapy*, **2020**, 21, 1675-1684	4	9
139	Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features. *Atherosclerosis*, **2020**, 312, 72-78	3.1	7
138	ApoCIII: A multifaceted protein in cardiometabolic disease. *Metabolism: Clinical and Experimental*, **2020**, 113, 154395	12.7	9
137	Association of Hypertriglyceridemia with All-Cause Mortality and Atherosclerotic Cardiovascular Events in a Low-Risk Italian Population: The TG-REAL Retrospective Cohort Analysis. *Journal of the American Heart Association*, **2020**, 9, e015801	6	17
136	HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). *Biomedicines*, **2020**, 8,	4.8	4

135	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 50-67	18.1	48
134	Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, 2531-2541	9.4	26
133	Nonalcoholic Fatty Liver Disease (NAFLD), But not Its Susceptibility Gene Variants, Influences the Decrease of Kidney Function in Overweight/Obese Children. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	16
132	ZBTB12 DNA methylation is associated with coagulation- and inflammation-related blood cell parameters: findings from the Moli-family cohort. *Clinical Epigenetics*, **2019**, 11, 74	7.7	7
131	Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, 665-674	9.4	16
130	Genetic and metabolic predictors of hepatic fat content in a cohort of Italian children with obesity. *Pediatric Research*, **2019**, 85, 671-677	3.2	16
129	Volanesorsen and Triglyceride Levels□n Familial Chylomicronemia Syndrome. *New England Journal of Medicine*, **2019**, 381, 531-542	59.2	192
128	Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease. *Liver International*, **2019**, 39, 2301-2308	7.9	11
127	Variation of PEAR1 DNA methylation influences platelet and leukocyte function. *Clinical Epigenetics* , **2019**, 11, 151	7.7	9
126	Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. *Journal of the Endocrine Society*, **2019**, 3, 2397-2410	0.4	18
125	A novel splicing mutation in the ABCA1 gene, causing Tangier disease and familial HDL deficiency in a large family. *Biochemical and Biophysical Research Communications*, **2019**, 508, 487-493	3.4	10
124	Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. *Scientific Reports*, **2018**, 8, 3702	4.9	40
123	Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. *Atherosclerosis*, **2018**, 271, 120-127	3.1	22
122	Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. *Journal of Clinical Lipidology*, **2018**, 12, 920-927.e4	4.9	59
121	Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. *Journal of Cardiovascular Medicine*, **2018**, 19, 83-90	1.9	9
120	Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes. *Journal of the American College of Cardiology*, **2018**, 71, 279-288	15.1	30
119	Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention. *Nutrition, Metabolism and Cardiovascular Diseases*, **2018**, 28, 197-205	4.5	24
118	The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study. *Expert Review of Cardiovascular Therapy*, **2018**, 16, 537-546	2.5	24

117	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". *Atherosclerosis*, **2018**, 275, 265-272	3.1	69
116	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Atherosclerosis*, **2018**, 277, 234-255	3.1	93
115	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. *Data in Brief*, **2018**, 21, 1334-1336	1.2	3
114	Prevalence and pharmacologic management of familial hypercholesterolemia in an unselected contemporary cohort of patients with stable coronary artery disease. *Clinical Cardiology*, **2018**, 41, 1075-1083	3.2	5
113	Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2018**, 1863, 991-997	5	9
112	Analysis of Children and Adolescents with Familial Hypercholesterolemia. *Journal of Pediatrics*, **2017**, 183, 100-107.e3	3.6	15
111	Early coronary calcifications are related to cholesterol burden in heterozygous familial hypercholesterolemia. *Journal of Clinical Lipidology*, **2017**, 11, 704-711.e2	4.9	25
110	Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. *Advances in Therapy*, **2017**, 34, 1200-1210	4.1	39
109	Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency. *Journal of Lipid Research*, **2017**, 58, 994-1001	6.3	10
108	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. *New England Journal of Medicine*, **2017**, 376, 1527-1539	59.2	390
107	Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically- versus genetically-driven excess fat hepatic storage. *Atherosclerosis*, **2017**, 257, 232-239	3.1	29
106	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). *Atherosclerosis Supplements*, **2017**, 29, 11-16	1.7	38
105	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. *Atherosclerosis Supplements*, **2017**, 29, 17-24	1.7	45
104	The approach study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). *Atherosclerosis*, **2017**, 263, e10	3.1	17
103	PNPLA3 variant and portal/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: a possible role for oxidative stress. *Scientific Reports*, **2017**, 7, 15756	4.9	34
102	Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 3340-3348	5.6	18
101	Neutral Lipid Storage Diseases: clinical/genetic features and natural history in a large cohort of Italian patients. *Orphanet Journal of Rare Diseases*, **2017**, 12, 90	4.2	34
100	Clinical and biochemical characteristics of individuals with low cholesterol syndromes: A comparison between familial hypobetalipoproteinemia and familial combined hypolipidemia. *Journal of Clinical Lipidology*, **2017**, 11, 1234-1242	4.9	19

99	Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol-diabetes connection? A systematic review of literature. *Acta Diabetologica*, **2017**, 54, 111-122	3.9	14
98	Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors. *Atherosclerosis*, **2017**, 256, 134-145	3.1	9
97	ANMCO Scientific Statement: clinical management of hypercholesterolaemia in patients with acute coronary syndromes. *European Heart Journal Supplements*, **2017**, 19, D64-D69	1.5	1
96	ANMCO Position Paper: diagnostic-therapeutic pathway in patients with hypercholesterolaemia and statin intolerance. *European Heart Journal Supplements*, **2017**, 19, D55-D63	1.5	6
95	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy. *European Heart Journal Supplements*, **2017**, 19, D3-D54	1.5	11
94	Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism. *Journal of Lipid Research*, **2016**, 57, 1097-107	6.3	38
93	The vitamin D receptor (VDR) gene rs11568820 variant is associated with type 2 diabetes and impaired insulin secretion in Italian adult subjects, and associates with increased cardio-metabolic risk in children. *Nutrition, Metabolism and Cardiovascular Diseases*, **2016**, 26, 407-13	4.5	13
92	A Novel Mutation in Gene Causing Tangier Disease in an Italian Family with Uncommon Neurological Presentation. *Frontiers in Neurology*, **2016**, 7, 185	4.1	12
91	Zofenopril or irbesartan plus hydrochlorothiazide in elderly patients with isolated systolic hypertension untreated or uncontrolled by previous treatment: a double-blind, randomized study. *Journal of Hypertension*, **2016**, 34, 576-87; discussion 587	1.9	7
90	Neutral lipid-storage disease with myopathy and extended phenotype with novel PNPLA2 mutation. *Muscle and Nerve*, **2016**, 53, 644-8	3.4	10
89	Contribution of mutations in low density lipoprotein receptor (LDLR) and lipoprotein lipase (LPL) genes to familial combined hyperlipidemia (FCHL): a reappraisal by using a resequencing approach. *Atherosclerosis*, **2015**, 242, 618-24	3.1	12
88	The history of Autosomal Recessive Hypercholesterolemia (ARH). From clinical observations to gene identification. *Gene*, **2015**, 555, 23-32	3.8	53
87	Circulating miR-33a and miR-33b are up-regulated in familial hypercholesterolaemia in paediatric age. *Clinical Science*, **2015**, 129, 963-72	6.5	45
86	Atherogenic dyslipidemia in children: evaluation of clinical, biochemical and genetic aspects. *PLoS ONE*, **2015**, 10, e0120099	3.7	7
85	Dyslipidemia and Cardiovascular Risk in Obesity **2015**, 121-130		1
84	Alterations of intestinal lipoprotein metabolism in diabetes mellitus and metabolic syndrome. *Atherosclerosis Supplements*, **2015**, 17, 12-6	1.7	13
83	Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. *European Journal of Internal Medicine*, **2014**, 25, 566-70	3.9	17
82	The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. *Atherosclerosis Supplements*, **2014**, 15, 1-15	1.7	62

81	Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on β2GPI-specific T cell response. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2014**, 34, 661-8	9.4	42
80	Arterial function and structure after a 1-year lifestyle intervention in children with nonalcoholic fatty liver disease. *Nutrition, Metabolism and Cardiovascular Diseases*, **2013**, 23, 1010-6	4.5	20
79	Subclinical myopathy in a child with neutral lipid storage disease and mutations in the PNPLA2 gene. *Biochemical and Biophysical Research Communications*, **2013**, 430, 241-4	3.4	25
78	Functional and morphological vascular changes in subjects with familial combined hypolipidemia: an exploratory analysis. *International Journal of Cardiology*, **2013**, 168, 4375-8	3.2	9
77	Heritability, genetic correlation and linkage to the 9p21.3 region of mixed platelet-leukocyte conjugates in families with and without early myocardial infarction. *Nutrition, Metabolism and Cardiovascular Diseases*, **2013**, 23, 684-92	4.5	8
76	Metabolic consequences of adipose triglyceride lipase deficiency in humans: an in vivo study in patients with neutral lipid storage disease with myopathy. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E1540-8	5.6	22
75	The angiopoietin-like protein 3: a hepatokine with expanding role in metabolism. *Current Opinion in Lipidology*, **2013**, 24, 313-20	4.4	29
74	Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. *Journal of Lipid Research*, **2013**, 54, 3481-90	6.3	55
73	Current challenges in the management of patients with familial hypercholesterolemia. *Clinical Lipidology*, **2013**, 8, 217-229		
72	Association of RXR-Gamma Gene Variants with Familial Combined Hyperlipidemia: Genotype and Haplotype Analysis. *Journal of Lipids*, **2013**, 2013, 517943	2.7	13
71	Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 1706-13	9.4	113
70	Does liver-derived ANGPTL3 play a role in cardiometabolic risk? Current evidence and future perspectives. *Clinical Lipidology*, **2013**, 8, 615-618		
69	Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E1266-75	5.6	87
68	Contribution of novel ATGL missense mutations to the clinical phenotype of NLSD-M: a strikingly low amount of lipase activity may preserve cardiac function. *Human Molecular Genetics*, **2012**, 21, 5318-28	5.6	41
67	Mechanisms of diabetic dyslipidemia: relevance for atherogenesis. *Current Vascular Pharmacology*, **2012**, 10, 684-6	3.3	62
66	Management of metabolic syndrome in children and adolescents. *Nutrition, Metabolism and Cardiovascular Diseases*, **2011**, 21, 455-66	4.5	56
65	Treating statin-intolerant patients. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, **2011**, 4, 155-66	3.4	51
64	The relationship between metabolic syndrome, its components, and the whole-body atherosclerotic disease burden as measured by computed tomography angiography. *Atherosclerosis* , **2011**, 215, 417-20	3.1	8

63	Severe coronary and extracoronary atherosclerosis in autosomal recessive hypercholesterolemia detected by whole-body computed tomography angiography. *Internal and Emergency Medicine*, **2011**, 6, 571-3	3.7	3
62	Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. *Circulation*, **2010**, 121, 52-62	16.7	76
61	Plasma non-cholesterol sterols: a useful diagnostic tool in pediatric hypercholesterolemia. *Pediatric Research*, **2010**, 67, 200-4	3.2	13
60	Genetic variants in adipose triglyceride lipase influence lipid levels in familial combined hyperlipidemia. *Atherosclerosis*, **2010**, 213, 206-11	3.1	7
59	Functional rs20417 SNP (-765G>C) of cyclooxygenase-2 gene does not predict the risk of recurrence of ischemic events in coronary patients: results of a 7-year prospective study. *Cardiology* , **2010**, 115, 236-42	1.6	6
58	Molecular imaging in atherosclerosis. *European Journal of Nuclear Medicine and Molecular Imaging*, **2010**, 37, 2381-97	8.8	32
57	Functional Lecithin: Cholesterol Acyltransferase Is Not Required for Efficient Atheroprotection in Humans. *Circulation*, **2009**, 1	16.7	82
56	Imaging coronary and extracoronary atherosclerosis: feasibility and impact of whole-body computed tomography angiography. *European Radiology*, **2009**, 19, 1704-14	8	12
55	Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment. *Nutrition, Metabolism and Cardiovascular Diseases*, **2009**, 19, 660-6	4.5	8
54	Prevalence and clinical features of heterozygous carriers of autosomal recessive hypercholesterolemia in Sardinia. *Atherosclerosis*, **2009**, 207, 162-7	3.1	24
53	Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. *Circulation*, **2009**, 120, 628-35	16.7	48
52	Clinical and genetic characterization of Chanarin-Dorfman syndrome. *Biochemical and Biophysical Research Communications*, **2008**, 369, 1125-8	3.4	60
51	Novel mutations in the adipose triglyceride lipase gene causing neutral lipid storage disease with myopathy. *Biochemical and Biophysical Research Communications*, **2008**, 377, 843-6	3.4	50
50	Detection of familial hypercholesterolemia in a cohort of children with hypercholesterolemia: results of a family and DNA-based screening. *Atherosclerosis*, **2008**, 196, 356-364	3.1	29
49	Mutations in the HFE gene and cardiovascular disease risk: an individual patient data meta-analysis of 53 880 subjects. *Circulation: Cardiovascular Genetics*, **2008**, 1, 43-50		22
48	C242T polymorphism of NADPH oxidase p22phox and recurrence of cardiovascular events in coronary artery disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 752-7	9.4	25
47	Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia. *Metabolism: Clinical and Experimental*, **2007**, 56, 1534-41	12.7	14
46	Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy. *Free Radical Biology and Medicine*, **2007**, 42, 698-705	7.8	72

45	Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease. *American Journal of Cardiology*, **2007**, 100, 1511-6	3	53
44	Autosomal recessive hypercholesterolemia in Spanish kindred due to a large deletion in the ARH gene. *Molecular Genetics and Metabolism*, **2007**, 92, 243-8	3.7	18
43	Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events. *Drugs*, **2007** , 67 Suppl 1, 29-42	12.1	30
42	Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. *Drugs*, **2007**, 67 Suppl 1, 43-54	12.1	24
41	Atorvastatin: its clinical role in cerebrovascular prevention. *Drugs*, **2007**, 67 Suppl 1, 55-62	12.1	13
40	Atorvastatin: a safety and tolerability profile. *Drugs*, **2007**, 67 Suppl 1, 63-9	12.1	12
39	99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques. *European Journal of Nuclear Medicine and Molecular Imaging*, **2006**, 33, 117-26	8.8	69
38	Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison. *Atherosclerosis*, **2006**, 188, 398-405	3.1	72
37	Tumor necrosis factor alpha (TNFalpha) and its soluble receptor p75 (sTNF-R p75) in familial combined hyperlipidemia (FCHL). *Nutrition, Metabolism and Cardiovascular Diseases*, **2005**, 15, 262-9	4.5	2
36	The adiponectin gene SNP+276G>T associates with early-onset coronary artery disease and with lower levels of adiponectin in younger coronary artery disease patients (age . *Journal of Molecular Medicine*, **2005**, 83, 711-9	5.5	105
35	Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. *Circulation*, **2005**, 111, 278-87	16.7	266
34	Congenital analbuminemia attributable to compound heterozygosity for novel mutations in the albumin gene. *Clinical Chemistry*, **2005**, 51, 1256-8	5.5	23
33	The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 1972-8	9.4	136
32	Adaptor protein ARH is recruited to the plasma membrane by low density lipoprotein (LDL) binding and modulates endocytosis of the LDL/LDL receptor complex in hepatocytes. *Journal of Biological Chemistry*, **2005**, 280, 38416-23	5.4	29
31	A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. *JAMA - Journal of the American Medical Association*, **2004**, 291, 2221-8	27.4	197
30	Association of the human adiponectin gene and insulin resistance. *European Journal of Human Genetics*, **2004**, 12, 199-205	5.3	108
29	The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity. *European Journal of Human Genetics*, **2004**, 12, 1050-4	5.3	46
28	Treatment of severe hypercholesterolemia with atorvastatin in congenital analbuminemia. *American Journal of Medicine*, **2004**, 117, 803-4	2.4	11

27	Genetic study of common variants at the Apo E, Apo AI, Apo CIII, Apo B, lipoprotein lipase (LPL) and hepatic lipase (LIPC) genes and coronary artery disease (CAD): variation in LIPC gene associates with clinical outcomes in patients with established CAD. *BMC Medical Genetics*, **2003**, 4, 8	2.1	33
26	Clinical and biochemical characterisation of patients with autosomal recessive hypercholesterolemia (ARH). *Nutrition, Metabolism and Cardiovascular Diseases*, **2003**, 13, 278-86	4.5	12
25	PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. *European Journal of Clinical Investigation*, **2002**, 32, 9-15	4.6	46
24	Molecular mechanisms of autosomal recessive hypercholesterolemia. *Human Molecular Genetics*, **2002**, 11, 3019-30	5.6	87
23	Human resistin gene, obesity, and type 2 diabetes: mutation analysis and population study. *Diabetes*, **2002**, 51, 860-2	0.9	101
22	Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. *Lancet, The*, **2002**, 359, 841-7	40	129
21	Common variants in the lipoprotein lipase gene, but not those in the insulin receptor substrate-1, the beta3-adrenergic receptor, and the intestinal fatty acid binding protein-2 genes, influence the lipid phenotypic expression in familial combined hyperlipidemia. *Metabolism: Clinical and Experimental*, **2002**, 51, 1298-305	12.7	15
20	The G972R variant of the insulin receptor substrate-1 (IRS-1) gene, body fat distribution and insulin-resistance. *Diabetologia*, **2001**, 44, 367-72	10.3	52
19	The G-308A variant of the Tumor Necrosis Factor-alpha (TNF-alpha) gene is not associated with obesity, insulin resistance and body fat distribution. *BMC Medical Genetics*, **2001**, 2, 10	2.1	37
18	Lack of association of the common TaqIB polymorphism in the cholesteryl ester transfer protein gene with angiographically assessed coronary atherosclerosis. *Clinical Genetics*, **2001**, 60, 374-80	4	27
17	Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. *Science*, **2001**, 292, 1394-8	33.3	448
16	The common mutations in the lipoprotein lipase gene in Italy: effects on plasma lipids and angiographically assessed coronary atherosclerosis. *Clinical Genetics*, **2000**, 58, 369-74	4	23
15	Haemochromatosis gene mutations and risk of coronary artery disease. *European Journal of Human Genetics*, **2000**, 8, 389-92	5.3	33
14	A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1999**, 19, 2975-80	9.4	67
13	Characterization of a new form of inherited hypercholesterolemia: familial recessive hypercholesterolemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1999**, 19, 802-9	9.4	79
12	Angiotensin-converting enzyme gene polymorphism is not associated with coronary atherosclerosis and myocardial infarction in a sample of Italian patients. *European Journal of Clinical Investigation*, **1998**, 28, 485-90	4.6	20
11	Low density lipoprotein receptor mutations in a selected population of individuals with moderate hypercholesterolemia. *Atherosclerosis*, **1998**, 136, 187-94	3.1	17
10	The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in italian patients. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1998**, 18, 1611-6	9.4	144

9	Hypercholesterolemia in Postmenopausal Women. *JAMA - Journal of the American Medical Association*, **1994**, 271, 453	27.4	31
8	Lipid control with low-dosage simvastatin in patients with moderate hypercholesterolaemia. An Italian multicentre double-blind placebo-controlled study. *European Heart Journal*, **1992**, 13 Suppl B, 11-6	9.5	12
7	Pravastatin vs Gemfibrozil in the Treatment of Primary Hypercholesterolemia. *Archives of Internal Medicine*, **1991**, 151, 146		21
6	Pravastatin in heterozygous familial hypercholesterolemia: low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblastS. *Metabolism: Clinical and Experimental*, **1991**, 40, 1074-8	12.7	13
5	Erythrocyte fatty acid composition and gallstone disease: results of an epidemiological survey. *American Journal of Clinical Nutrition*, **1987**, 46, 110-4	7	5
4	Plasma cholesterol response to a change in dietary fat intake: a collaborative twin study. *Journal of Chronic Diseases*, **1985**, 38, 927-34		9
3	PREVALENCE OF GALLSTONE DISEASE IN AN ITALIAN ADULT FEMALE POPULATION. *American Journal of Epidemiology*, **1984**, 119, 796-805	3.8	230
2	Plasma and erythrocyte fatty acids: a methodology for evaluation of hypocholesterolemic dietary interventions. *Preventive Medicine*, **1983**, 12, 124-7	4.3	17
1	Circulating platelet aggregates in an adult population sample. Relationships with the main coronary risk factors and cardiovascular diseases. *Atherosclerosis*, **1980**, 35, 375-81	3.1	3